Physician profile
Daniel L Cox
NPI 1417059254
$13,404.46
in general payments reported to CMS, 2019-2025
48 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,700 · 2020: $1,788 · 2021: $1,739 · 2022: $2,155 · 2023: $1,924 · 2024: $2,217 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,898 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,898.08 |
| Education | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,465.31 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,440.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,152.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,140.86 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $769.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.72 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $670.51 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $629.51 | 2022-2025 | |
| Glaxosmithkline, LLC. | $627.56 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $362.72 | 2019-2023 | |
| Allergan, INC. | $323.55 | 2019-2021 | |
| Amgen INC. | $322.60 | 2019-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $272.34 | 2019-2024 | |
| Antares Pharma, INC. | $267.19 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| E.R. Squibb & Sons, L.L.C. | $258.53 | 2019-2023 | Eliquis, Camzyos |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.